Biostar Capital

Biostar Capital is an early-stage medical device fund based in Charlevoix, Michigan, structured around a network of practicing clinicians who source, diligence, and support investments. The portfolio includes Amplitude Vascular Systems, which signals an interest in vascular and interventional device platforms. The fund is not AI-focused; the value-add is clinical: surgeon advisors who can validate procedural fit, refine product-market fit at the bedside, and open KOL networks. For device founders, that clinical depth is often more useful at the seed stage than additional dollars.

Biostar invests at Seed and Series A with checks of $1M to $5M, positioning it to lead small device rounds or co-lead alongside larger MedTech specialists. The fund deploys across the US rather than limiting to the Midwest, despite the Charlevoix base.

Founders should approach Biostar when they are building a transformational device — vascular, interventional, surgical — and want a fund whose clinical advisory bench can shape the product before commercialization. Pure software, digital therapeutics, and biotech are out of scope. The clinician-driven model means partners will probe procedural details, surgeon training requirements, and reimbursement-coding strategy early. Founders should arrive with engineering proof points, a clear procedural workflow, and an openness to incorporating surgeon feedback into the device roadmap rather than treating advisors as a check-the-box exercise.